Introduction
============

Spindle cell melanoma (SCM) is a rare subtype of malignant melanoma composed of spindled neoplastic cells arranged in sheets and fascicles ([@b1-ol-0-0-9247]). The diagnosis of SCM is challenging, as SCM may occur anywhere on the body and frequently mimics amelanotic lesions, including scarring and inflammation ([@b2-ol-0-0-9247]--[@b4-ol-0-0-9247]). Histologically, cytologic features of SCM are indistinct and often confused with those of other epithelial neoplasms, including sarcomas and lymphomas ([@b5-ol-0-0-9247]--[@b8-ol-0-0-9247]). Immunohistochemistry is a helpful tool in distinguishing SCM from other sarcomas and carcinomas ([@b9-ol-0-0-9247],[@b10-ol-0-0-9247]). However, diagnosis remains a challenge as a number of sarcomas share some morphological and immunohistochemical features with SCM ([@b5-ol-0-0-9247],[@b11-ol-0-0-9247]). Differentiation of SCM from desmoplastic melanoma is difficult because both melanomas are characterized by atypical, spindled, malignant melanocytes. However, the size of spindle cell collagen areas and the immunohistochemical markers, S100, MelanA and Tyrosinase, allow differential diagnosis ([@b10-ol-0-0-9247]). Therefore, the integration of clinical and histological assessment is essential for the diagnosis of SCM ([@b2-ol-0-0-9247],[@b8-ol-0-0-9247]). Diagnosis of SCM is often delayed until patients exhibit advanced-stage disease, typically with widespread metastasis and poor treatment outcomes ([@b3-ol-0-0-9247],[@b6-ol-0-0-9247],[@b12-ol-0-0-9247],[@b13-ol-0-0-9247]).

A limited number of case reports and incomplete retrospective case studies of the differential diagnostic viewpoints of SCM exist ([@b3-ol-0-0-9247],[@b4-ol-0-0-9247],[@b11-ol-0-0-9247]--[@b15-ol-0-0-9247]). To the best of our knowledge, few studies have reported SCM incidence, clinicopathologic features, treatment, treatment outcome and disease-specific independent prognostic factors. Thus, the present study performed a retrospective analysis of a series of clinical cases using data from the Surveillance, Epidemiology and End Results (SEER) Program.

Materials and methods
=====================

### Data collection

In the present study, data was analyzed from the SEER Program, National Cancer Institute Public Use Dataset, which contains publically available records of 18 population-based cancer registries, which together represent 28% of the USA population. Data were extracted regarding patients with a primary diagnosis of SCM, according to the International Classification of Diseases for Oncology, Third Edition (ICD-O-3), using histology codes: 8772/3 ([@b16-ol-0-0-9247]). Cases were excluded if treatment or outcome data were unavailable for survival analysis. The data extraction was carried out with the official software SEER\*Stat, version 8.3.4. (URL: <http://seer.cancer.gov/data/>).

### Statistical analyses

Overall Statistical analysis was accomplished using Statistical Package for Social Sciences (SPSS; version 23.0, for Windows; IBM Corp., Armonk, IL, USA). χ^2^ test or Fisher\'s exact test was used to analyze associations among baseline parameters. The primary endpoint in the present study was considered to be the date of SCM-associated mortality. The time point between the date of diagnosis and the date of SCM-associated mortality was defined as disease-specific survival (DSS). Mortalities associated with SCM were considered to be events, while deaths attributed to other causes were considered to be 'censored observations'. In terms of overall survival (OS) and DSS rates, Kaplan-Meier method and the log-rank test were utilized and multivariate Cox proportional hazard models were used to identify significant risk factors for survival outcomes. All statistical tests were two-sided, and P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Study population and characteristics

The following demographic and clinicopathological characteristics were selected for analysis: Age at diagnosis, ethnicity, primary tumor location, Tumor-Node-Metastasis (TNM) stage, American Joint Committee on Cancer (AJCC) stage, pathological grade (the American Joint Committee on Cancer/Union for International Cancer Control staging system), SEER historic stage, treatment modalities, vital status and follow-up time ([@b17-ol-0-0-9247]). Unfortunately, complete data was not available for all cases.

Data from 4,761 patient diagnosed with SCM between 1973 and 2017 was retrieved from the SEER database. The total cohort consisted of 1,829 women and 2,932 men, with a female:male ratio of 0.62:1. The patients\' age ranged from 3--101 years and a median age of 66 years. The age and sex distributions are presented in [Fig. 1](#f1-ol-0-0-9247){ref-type="fig"}. The median follow-up time was 53 months (range, 0--500 months). Regarding ethnicity, Caucasian people accounted for 96.7% of the study population. The majority of the cases of SCM had originated from the skin, and the eye and bony orbits were the second-most affected tumor site. Surgical resection was performed in 88.7% cases. The basic demographic and clinicopathologic characteristics of the whole patients are summarized in [Table I](#tI-ol-0-0-9247){ref-type="table"}. Kaplan-Meier analysis was utilized for time-to-event analysis. Statistically significant differences in OS rate were identified depending on age (P\<0.001), sex (P\<0.001), tumor location (P\<0.001), ethnicity (P=0.008), AJCC stage (P\<0.001), T stage (P\<0.001), pathological grade (P\<0.001), N stage (P\<0.001), treatment modalities (P\<0.001) and M stage (P\<0.001) ([Fig. 2](#f2-ol-0-0-9247){ref-type="fig"}). Univariate Cox regression analysis analysis revealed that age, ethnicity, sex, tumor location, pathological grade, AJCC stage, T stage, N stage, M stage, SEER historic stage and treatment modalities were associated with OS ([Table II](#tII-ol-0-0-9247){ref-type="table"}). Multivariate Cox regression analysis revealed that positive N stage, age \>66 years and SEER historic stage of regional and distant metastasis were factors independently associated with worse OS ([Table III](#tIII-ol-0-0-9247){ref-type="table"}).

Significant differences in the DSS analysis were also identified depending on age (P\<0.001), sex (P\<0.001), pathological grade (P\<0.001), AJCC stage (P\<0.001), ethnicity (P=0.009), T stage (P\<0.001), tumor location (P\<0.001), M stage (P\<0.001), treatment modalities (P\<0.001), and SEER historic stage (P\<0.001) ([Fig. 3](#f3-ol-0-0-9247){ref-type="fig"}). Univariate Cox regression analysis demonstrated that age, ethnicity, sex, tumor location, pathological grade, AJCC stage, T stage, N stage, M stage, SEER historic stage and treatment modalities were associated with DSS ([Table II](#tII-ol-0-0-9247){ref-type="table"}). The multivariate Cox regression model revealed that age \>66 years T3+T4 stage, positive N-stage and SEER historic stage of regional and distant metastasis were independently associated with a poor OS rate ([Table III](#tIII-ol-0-0-9247){ref-type="table"}).

Discussion
==========

As a morphological variant of melanoma, SCM is rare and its incidence has been variably reported between 3 and 14% of all melanoma cases (including desmoplastic melanoma) ([@b15-ol-0-0-9247],[@b18-ol-0-0-9247],[@b19-ol-0-0-9247]). Diagnosis of SCM is challenging and awareness of its clinical and cytological features as well as immunohistochemical markers are essential to reach the correct diagnosis ([@b9-ol-0-0-9247],[@b10-ol-0-0-9247],[@b15-ol-0-0-9247]). Due to the rarity of SCM, its clinical and prognostic characteristics remain to be fully elucidated. To the best of our knowledge, the present study is the first to investigate SCM incidence as well as survival analysis on a large scale.

The present study demonstrates that the incidence of SCM was highest in the 6--8th decade of life in males. Caucasian people accounted for the majority of the study population. SCM lesions originated most commonly from the skin and eyes, and the bony orbits were the second-most affected tumor site. SCM shares various features with conventional melanoma. Previous studies have demonstrated that melanomas arise from the melanocytes of the skin and eyes in response to intrinsic and extrinsic stimuli, including pro-inflammatory signals, oncogenes and UV radiation ([@b12-ol-0-0-9247],[@b20-ol-0-0-9247],[@b21-ol-0-0-9247]). Human pigmentation is a polygenic quantitative trait with high heritability and it is modulated by estrogen and androgens via regulation of melanin synthesis ([@b22-ol-0-0-9247]). This may explain why SCM mainly originates from skin and eyes and has a predilection of male and Caucasian people.

According to previous studies, it appears that age, sex, ethnicity and tumor location are important prognostic factors for patients with melanoma ([@b22-ol-0-0-9247]--[@b24-ol-0-0-9247]). The present study indicates that patients with SCM who were male, aged \>66 years, Caucasian, or with tumors located in the skin were associated with poor OS and DSS rates. In the multivariate Cox regression analysis, age \>66 years was independently associated with poor OS and DSS rates, which was in consistence with previous studies on melanoma ([@b24-ol-0-0-9247]--[@b27-ol-0-0-9247]). Seeing as it was demonstrated that SCM was more likely to occur in patients \>66 years of age, potential poor tolerance of complications and common comorbidities of elderly patients should be also taken into consideration when making treatment protocol.

Pathological grade has been demonstrated to be an important prognostic factor for estimation of survival outcome in melanoma ([@b17-ol-0-0-9247]). The results of the present study indicate that well-differentiated SCM was associated with a relatively good outcome both in terms of OS and DSS rate, compared with poorly differentiated SCM. Advanced stage SCM was associated with a relatively poor OS and DSS rates compared with early-stage tumors. Cox multivariate regression also suggested that pathology was an important consideration, with advanced T stage, positive N stage and SEER historic stage of metastasis being independently associated with poor OS and DSS rates. This emphasizes that a full awareness of the morphological and clinical presentations of SCM are required for the accurate diagnosis of SCM. However, due to the unspecific clinical presentation of SCM, early detection is often delayed ([@b4-ol-0-0-9247],[@b12-ol-0-0-9247]--[@b14-ol-0-0-9247]). Metastatic SCM from an unknown primary site should be taken into consideration when diagnosing SCM lesions ([@b15-ol-0-0-9247],[@b18-ol-0-0-9247],[@b28-ol-0-0-9247]). Fine-needle aspiration may be a rapid and effective tool for surveillance of recurrent and metastatic cases of SCM, however, accurate diagnosis is challenging owing to the varied cytologic morphologic appearances ([@b6-ol-0-0-9247],[@b29-ol-0-0-9247]--[@b31-ol-0-0-9247]).

In the present study, surgery was the only identified treatment modality for SCM. The results indicate that surgery was favorable for OS and DSS rates. A previous study demonstrated that wide local excision with clear margins, sentinel node biopsy and regular follow-up examinations were crucial in the management of SCM ([@b4-ol-0-0-9247]). However, SCM cases should be monitored carefully as metastasis is possible fir multiple years after surgery ([@b32-ol-0-0-9247]). For tumors in complex anatomic regions, including the head and neck, the treatment of elderly patients or those at an advanced stage by radical surgery with clear margins is difficult ([@b3-ol-0-0-9247]). Under these circumstances, therapeutic planning is challenging ([@b33-ol-0-0-9247]). Therefore, multi-cancer randomized clinical trials are urgently required to improve the available treatment for this melanoma subtype.

While the SEER Program is a comprehensive and geographically representative registry, a few limitations of the present study should be noted. Due to alterations of the criteria for the histological diagnosis of SCM the diagnosis of SCM patients in the past may be inconsistent with more recent diagnoses. Another limitation is that complete data was not available for all cases. A number of important prognostic data, including surgical types, margin status and adjuvant therapies were either absent or incomplete in the available SEER data, and therefore there influence on prognosis could not be assessed. In addition, the results suggest that SCM patients may represent an older population, and data on comorbidities that may affect treatment protocols and outcomes is lacking. To the best of our knowledge, this is the first large population study of SCM with a robust long-term follow-up survival assessment provided by SEER, which will improve the existing knowledge of the demographic of SCM, its clinicopathological features and disease-specific prognostic factors.

Overall, a large scale report of SCM demographic trends, clinicopathological features, treatment outcomes and disease-specific independent prognostic factors was presented. The results demonstrate that SCM mostly occurred in Caucasians and males, and the highest incidence occurred in the 6--8th decades of life. Age, ethnicity, T stage, N stage and SEER historic stage were independent prognostic factors of DSS and OS rates.
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###### 

The baseline characteristics of the SCM cases extracted from the SEER database.

                           DSS     OS                              
  ------------------------ ------- ----- --------- ------- ------- ---------
  Age                                                              
    ≤66 years              1,333   361   \<0.001   1,512   621     \<0.001
    \>66 years             710     406             1,095   1,533   
  Sex                                                              
    Female                 878     274   \<0.001   1,066   763     \<0.001
    Male                   1,165   493             1,541   1,391   
  Ethnicity                                                        
    White                  1,947   745   0.009     2,506   2,098   0.008
    Black                  16      9               17      17      
    Others                 80      13              84      39      
  Tumor location                                                   
    Eyes and bony orbits   383     118   \<0.001   433     294     \<0.001
    Internal organs        7       14              9       21      
    Nose and mouth         18      20              19      29      
    Skin                   1,624   587             2,131   1,766   
    Other site             11      28              15      44      
  Grade                                                            
    I                      26      4     \<0.001   30      8       \<0.001
    II                     16      1               20      8       
    III                    16      20              20      40      
    IV                     12      16              15      31      
    Unknown                1,973   726             2,522   2,067   
  AJCC stage                                                       
    I                      552     42    \<0.001   745     184     \<0.001
    II                     533     118             729     371     
    III                    138     57              176     115     
    IV                     36      73              50      115     
  T stage                                                          
    T0                     22      26    \<0.001   30      40      \<0.001
    T1                     394     38              524     148     
    T2                     345     44              451     154     
    T3                     244     60              347     178     
    T4                     278     117             375     284     
    TX                     99      42              144     125     
  N stage                                                          
    N0                     1,226   210   \<0.001   1,656   683     \<0.001
    N1                     57      46              77      79      
    N2                     35      16              46      38      
    NX                     65      55              93      129     
  M stage                                                          
    M0                     1,324   246   \<0.001   1,796   779     \<0.001
    M1                     34      73              48      114     
    MX                     25      8               28      36      
  SEER stage                                                       
    Localized              1,499   305   \<0.001   1,893   1,133   \<0.001
    Regional               419     263             547     632     
    Distant                8       9               14      18      
    Unknown                70      53              88      143     
  Treatment                                                        
    Non-surgery            208     109   0.011     266     255     0.195
    Surgery                1,827   655             2,332   1,891   
    Unknown                8       3               9       8       

SCM, spindle cell melanoma; OS, overall survival; DSS, disease specific survival; T, tumor; N, node; M, metastasis; SEER, the Surveillance, Epidemiology and End Results; AJCC stage, American joint committee on cancer stage. TX, T stage unknown; NX, N stage unknown; MX, M stage unknown.

###### 

Univariate Cox regression analysis in terms of DSS and OS rates of SCM

                          DSS                       OS                                 
  ----------------------- ------------------------- --------- ------------------------ ---------
  Age                                                                                  
    ≤66 years             1.0 (reference)           \<0.001   1.0 (reference)          \<0.001
    \>66 years            2.372 (2.054--2.739)                3.594 (3.257--3.965)     
  Ethnicity                                                                            
    Caucasian             1.0 (reference)                     1.0 (reference)          
    Black                 1.430 (0.741--2.760)      0.286     1.345 (0.835--2.169)     0.223
    Others                0.497 (0.287--0.861)      0.013     0.602 (0.439--0.827)     0.002
  Sex                                                                                  
    Female                1.0 (reference)           \<0.001   1.0 (reference)          \<0.001
    Male                  1.403 (1.210--1.627)                1.355 (1.240--1.481)     
  Tumor location                                                                       
    Eye and bony orbits   1.0 (reference)                     1.0 (reference)          
    Internal organs       5.461 (3.132--9.522)      \<0.001   3.817 (2.449--5.948)     \<0.001
    Nose and mouth        3.824 (2.377--6.151)      \<0.001   3.231 (2.204--4.738)     \<0.001
    Skin                  1.413 (1.159--1.722)      0.001     1.642 (1.450--1.860)     \<0.001
    Other site            5.735 (3.790--8.679)      \<0.001   3.877 (2.821--5.329)     \<0.001
  Grade                                                                                
    I                     1.0 (reference)                     1.0 (reference)          
    II                    0.247 (0.028--2.209)      0.211     0.864 (0.324--2.304)     0.771
    III                   4.496 (1.536--13.154)     0.006     3.405 (1.593--7.278)     0.002
    IV                    5.303 (1.773--15.867)     0.003     3.923 (1.802--8.537)     0.001
    Unknown               1.508 (0.564--4.209)      0.413     1.781 (0.889--3.566)     0.104
  AJCC stage                                                                           
    I                     1.0 (reference)                     1.0 (reference)          
    II                    2.892 (2.033--4.113)      \<0.001   2.072 (1.736--2.474)     \<0.001
    III                   5.966 (4.002--8.895)      \<0.001   2.896 (2.293--3.658)     \<0.001
    IV                    25.917 (17.641--38.075)   \<0.001   10.091 (7.968--12.781)   \<0.001
  T stage                                                                              
    T0                    1.0 (reference)                     1.0 (reference)          
    T1                    0.087 (0.053--0.143)      \<0.001   0.214 (0.151--0.304)     \<0.001
    T2                    0.113 (0.069--0.183)      \<0.001   0.267 (0.189--0.378)     \<0.001
    T3                    0.217 (0.137--0.344)      \<0.001   0.392 (0.278--0.552)     \<0.001
    T4                    0.391 (0.256--0.599)      \<0.001   0.609 (0.437--0.848)     0.003
    TX                    0.378 (0.232--0.617)      \<0.001   0.627 (0.439--0.895)     0.010
  N stage                                                                              
    N0                    1.0 (reference)                     1.0 (reference)          
    N1                    4.273 (3.103--5.883)      \<0.001   2.320 (1.837--2.929)     \<0.001
    N2                    3.448 (2.072--5.737)      \<0.001   2.296 (1.656--3.185)     \<0.001
    NX                    4.812 (3.572--6.483)      \<0.001   3.306 (2.737--3.994)     \<0.001
  M stage                                                                              
    M0                    1.0 (reference)                     1.0 (reference)          
    M1                    10.339 (7.923--13.491)    \<0.001   5.559 (4.556--6.783)     \<0.001
    MX                    1.337 (0.661--2.705)      0.419     1.783 (1.276--2.491)     0.001
  SEER stage                                                                           
    Localized             1.0 (reference)                     1.0 (reference)          
    Regional              2.914 (2.469--3.439)      \<0.001   1.921 (1.742--2.119)     \<0.001
    Distant               20.058(10.243--39.278)    \<0.001   8.328 (5.204--13.328)    \<0.001
    Unknown               2.828 (2.112--3.786)      \<0.001   1.791 (1.505--2.132)     \<0.001
  Treatment                                                                            
    Non-surgery           1.0 (reference)                     1.0 (reference)          
    Surgery               0.671 (0.548--0.822)      \<0.001   0.761 (0.667--0.867)     \<0.001
    Unknown               0.649 (0.206--2.044)      0.460     0.679 (0.336--1.374)     0.282

SCM, spindle cell melanoma; OS, overall survival; DSS, disease specific survival; SEER, the Surveillance, Epidemiology and End Results; AJCC, American joint committee on cancer; HR, hazard ratio; CI, confidence interval; TX, T stage unknown; NX, N stage unknown; MX, M stage unknown. Reference was used as the parameter against which HR was calculated.

###### 

Multivariate Cox regression analysis of SCM for DSS and OS rates.

                  DSS                        OS                                  
  --------------- -------------------------- --------- ------------------------- ---------
  Age                                                                            
    ≤66 years     1.0 (reference)            \<0.001   1.0 (reference)           \<0.001
    \>66 years    2.502 (1.900--3.296)                 3.799 (3.160--4.568)      
  Ethnicity                                                                      
    Caucasian     1.0 (reference)                      1.0 (reference)           
    Black         2.286 (0.727--7.196)       0.157     2.664 (1.187--5.980)      0.018
    Others        1.564 (0.690--3.544)       0.284     1.297 (0.731--2.303)      0.374
  T stage                                                                        
    TX+T0+T1+T2   1.0 (reference)            \<0.001   1.0 (reference)           \<0.001
    T3+T4         2.113 (1.567--2.847)                 1.485 (1.261--1.749)      
  N stage                                                                        
    Negative      1.0 (reference)            \<0.001   1.0 (reference)           0.001
    Positive      2.437 (1.617--3.673)                 1.564 (1.204--2.031)      
  SEER stage                                                                     
    Localized     1.0 (reference)                      1.0 (reference)           
    Regional      1.682 (1.199--2.361)       0.003     1.458 (1.208--1.760)      \<0.001
    Distant       57.206 (22.241--147.138)   \<0.001   18.856 (10.145--35.047)   \<0.001

SCM, spindle cell melanoma; OS overall survival; DSS, disease specific survival; SEER, the Surveillance, Epidemiology and End Results; AJCC, American joint Committee on Cancer; HR, hazard ratio; CI, confidence interval; TX, T stage unknown. Reference was used as the parameter against which HR was calculated.
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